Prodrugs comprising an insulin linker conjugate

US9457066B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Harald Rau · Würzburg, DE
• Felix Cleemann · Mainz, DE
• Ulrich Hersel · Heidelberg, DE
• Silvia Kaden-Vagt · Heidelberg, DE
• Torben Lessmann · Neustadt an der Weinstraße, DE
• Thomas Wegge · Heidelberg, DE

Key dates

• Filing date: May 14, 2015
• Grant date: Oct 4, 2016
• Expiry date: May 14, 2035

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10T428/2982
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an insulin linker conjugate D-L, wherein D represents the insulin moiety; and -L is a non-biologically active linker moiety -L1 represented by formula (I),wherein the dashed line indicates the attachment to one of the amino groups of the insulin by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by insulin.